Treatment News : Gilead 'Quad' Performed Similarly to Atripla in Phase III Study

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » August 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

August 15, 2011

Gilead 'Quad' Performed Similarly to Atripla in Phase III Study

A study of Gilead Science’s "quad" fixed-dose combination tablet containing the experimental integrase inhibitor elvitegravir and boosting agent cobicistat, along with tenofovir and emtricitabine, has met its primary objective—"non-inferiority" compared to mainstay therapy Atripla—according to an announcement by the company.  

According to Gilead—full results have not yet been presented or published—88 percent of those who took the quad tablet in the study had undetectable viral loads (less than 50 copies) after 48 weeks of treatment, compared with 84 percent of those who took Atripla.  The clinical trial enrolled 352 people living with HIV starting antiretroviral therapy for the first time. 

CD4 increases were significantly more substantial among those receiving the quad compared to Atripla: 239 versus 206 cells, respectively.

The company claims rates of moderate-to-severe adverse events were similar between the quad-treated and Atripla-treated groups. Discontinuation rates due to adverse events were comparable in both groups of the study.

The Phase III research program for Gilead’s quad tablet includes two studies (Studies 102 and 103) evaluating the all-in-one regimen versus a standard of care among people starting HIV treatment for the first time. Like the encouraging results from Study 102, highlighted in the Gilead statement, data from a Phase II study also suggest the quad has similar efficacy to Atripla.
 
Study 103, still under way, is comparing the efficacy, safety and tolerability of the quad tablet, compared with Norvir (ritonavir)-boosted Reyataz (atazanavir) combined with Truvada (tenofovir plus emtricitabine).

Gilead plans to submit the results from Study 102 for presentation at a scientific conference early next year.

Search: Gilead, quad, elvutegravir, integrase inhibitor, Truvada, Viread, Emtriva, tenofovir, emtricitabine, cobicistat


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.